Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
IPO Year: 2015
Exchange: NASDAQ
Website: aclaristx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $8.00 | Outperform | Wedbush |
| 3/18/2025 | Overweight | Cantor Fitzgerald | |
| 12/23/2024 | $20.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2024 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/19/2024 | $2.00 → $7.00 | Market Perform → Outperform | Leerink Partners |
| 11/19/2024 | $8.00 | Neutral → Buy | BTIG Research |
| 11/19/2024 | $2.00 → $7.00 | Hold → Buy | Jefferies |
| 11/18/2024 | $3.00 → $13.00 | Neutral → Overweight | Piper Sandler |
| 1/22/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/13/2023 | Outperform → Mkt Perform | William Blair |
SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
SCHEDULE 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
DEFA14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
DEF 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
PRE 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
EFFECT - Aclaris Therapeutics, Inc. (0001557746) (Filer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res
- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf
- Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl
– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis," said Dr. Neal Walker, Interim President & CEO and Chair of
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement wi
- Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update. "We are pleased to announce that following a review of the potential development pathways for ATI-2138, our investigational ITK/JAK3 compound with best-in-class potential, we have decided to progress ATI-2138 into a proof-of-concept Phase 2a trial in patients with moderate to
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the "Investors" page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at leas
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. "As we enter 2024, we are financially strong, focused and motivated," stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. "Returning to the CEO role, I look forward to building on our strong foundation and deep expertise in kinase discovery and development as we look to shape the future of Aclaris." Research and Development Hi
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202). ATI-450-RA-202 is a Phase 2b, randomized, multicenter, double-blind,
- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update. "Throughout the first three quarters of this year, I believe our company has performed remarkably well in terms of executing across our clini
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June. On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY.On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a fireside chat
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright "HCW@Home" series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days. About Ac
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody. "Therapeutic innovation is at the core of the important work we do at Aclaris, and bispecific antibodies represent a groundbreaking innovation in i
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.On Thursday March 27, 2025, at 9:00 AM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a
- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases. This was published in The Journal of Pharmacology and Expe
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D., and Zuzana Diamant, M.D., Ph.D. leading experts in respiratory medicine, clinical pharmacology, and immunology. "We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris Therapeutics.
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris' Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the "2024 Inducement Plan"). The stock options and restricted stock units were granted as inducements material to the new employ
Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00
Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight
H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00
Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight
Leerink Partners upgraded Aclaris Therapeutics from Market Perform to Outperform and set a new price target of $7.00 from $2.00 previously
BTIG Research upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $8.00
Jefferies upgraded Aclaris Therapeutics from Hold to Buy and set a new price target of $7.00 from $2.00 previously
Piper Sandler upgraded Aclaris Therapeutics from Neutral to Overweight and set a new price target of $13.00 from $3.00 previously
H.C. Wainwright downgraded Aclaris Therapeutics from Buy to Neutral
William Blair downgraded Aclaris Therapeutics from Outperform to Mkt Perform
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. "We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records," said Neal Walker, Chief Executive Officer of Aclaris. "Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors." Mr. Doody has nearly 20 years of biotechnology i
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and Chief Operating Officer. Dr. Manion will be responsible for overseeing day-to-day operations, continuing to develop Aclaris' infrastructure and helping Aclaris develop its vision and overall strategic direction alongside Neal Walker, Aclaris' CEO, and Aclaris' board of directors. "We are excited to strengthen our leadership team by welcomi
Appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Gail Cawkwell, MD, PhD, as Chief Medical Officer, effective today. "We are excited to welcome Dr. Cawkwell to Aclaris at this time as we are executing on a number of clinical programs," said Dr. Neal Walker, President and CEO of Aclaris. "Her leadership experience in pharmaceutical development as well as her clinical background will be extremely valuable in navigating the strategic directi
Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022. "We are excited to welcome Jim to Aclaris," said Dr. Neal Walker, President and CEO of Aclaris. "His experience as a business development leader in the life sciences industry will be extremely valuable in executing our global business development strategy for our drug development pipeline." Mr. Loerop brings over two decades of exper